Could a Hidden Genetic Risk Be Delaying Diabetes Diagnosis in Men?

Synopsis
Key Takeaways
- G6PD deficiency affects over 400 million people worldwide.
- Men with this condition may be diagnosed with type 2 diabetes four years later.
- They face a 37% higher risk of diabetes-related complications.
- Current testing methods may not accurately reflect blood sugar levels for those with G6PD deficiency.
- Routine screenings could significantly improve health outcomes.
New Delhi, Sep 30 (NationPress) A prevalent gene variant may be causing delays in the diagnosis of type 2 diabetes for millions of men globally, while also heightening their risk for severe complications, as revealed by a recent study.
G6PD deficiency is a genetic disorder impacting over 400 million individuals across the globe, with a notable prevalence among people of African, Asian, Middle Eastern, and Mediterranean descent.
This condition is more frequently found in men and often remains undiagnosed due to its lack of obvious symptoms. The World Health Organization (WHO) recommends routine testing for G6PD deficiency in populations at risk, yet such practices are not universally adopted.
Researchers from the University of Exeter, working alongside Queen Mary University of London (QMUL), discovered that men with G6PD deficiency receive their type 2 diabetes diagnosis an average of four years later than those without the gene variant. Alarmingly, less than 2% of these men have been diagnosed.
The findings, published in the journal Diabetes Care, indicated that men with G6PD deficiency face a 37% greater risk of developing diabetes-related microvascular complications, including damage to the eyes, kidneys, and nerves, compared to their counterparts without this deficiency.
While G6PD deficiency does not directly cause diabetes, it can result in an artificially low reading on the HbA1c blood test, which is typically used to diagnose and monitor diabetes.
This misrepresentation can lead to delayed diagnoses and treatment, prompting researchers to advocate for the development of advanced diagnostic techniques before serious complications arise.
"Our findings underscore the critical need for reform in testing practices to address health disparities. Healthcare providers and policymakers must recognize that the HbA1c test may not be reliable for those with G6PD deficiency, and implementing routine G6PD screenings could be vital in identifying at-risk individuals. This issue is paramount not only for healthcare but for health equity as a whole," stated Professor Inês Barroso from the University of Exeter.
The HbA1c blood test serves as the global standard for managing type 2 diabetes and is utilized in 136 nations for diabetes diagnosis.
Nonetheless, for individuals with G6PD deficiency, this test may underestimate blood sugar levels, leading to significant medical delays and an increased risk of serious complications.